Growth ⏱ Half-life: Approximately 8 days due to albumin conjugation via the DAC moiety.

CJC-1295 DAC

CJC-1295 with Drug Affinity Complex

Buy from $44.99 →
Half-Life
Approximately 8 days due to albumin conjugation via the DAC moiety.
Mol. Weight
3647.28 g/mol

What is CJC-1295 DAC?

CJC-1295 DAC is the extended-release version of the GHRH analog CJC-1295, modified with a Drug Affinity Complex that binds to albumin in the bloodstream. This dramatically extends its active duration from minutes to over a week.

Research Applications

Sustained GH axis stimulation, long-term IGF-1 elevation studies, body composition research, and comparative studies against pulsatile GHRH protocols.

Dosage Information (Research Use)

Research protocols: 1-2 mg subcutaneously once or twice weekly. The sustained release reduces injection frequency compared to non-DAC version. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution. Dissolves readily.

Half-Life & Pharmacokinetics

Approximately 8 days due to albumin conjugation via the DAC moiety.

Reported Observations in Literature

Similar to other GHRH analogs: flushing, water retention, tingling. Continuous GH elevation may amplify effects compared to pulsatile protocols.

Key Research References

  • Teichman SL, et al. “Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults.” J Clin Endocrinol Metab. 2006

How CJC-1295 DAC Works

CJC-1295 DAC is the Drug Affinity Complex version of Modified GRF(1-29). The DAC moiety binds covalently to serum albumin after injection, extending the half-life from ~30 minutes to approximately 8 days. This creates sustained, elevated GH levels rather than the pulsatile pattern seen with the no-DAC version. While this produces higher total GH output, the non-physiological continuous elevation has led many researchers to prefer the no-DAC version for more natural pulsatile release patterns.

Research Findings

Published data shows sustained IGF-1 elevation for 7-10 days after a single subcutaneous injection. Less commonly used than the no-DAC variant in modern research protocols due to preference for pulsatile GH release.

Dosage & Administration

Research protocols: 1-2 mg subcutaneously once or twice weekly. The sustained release reduces injection frequency compared to non-DAC version. Research use only.

Safety & Side Effects

Similar to other GHRH analogs: flushing, water retention, tingling. Continuous GH elevation may amplify effects compared to pulsatile protocols.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Modified GRF(1-29) with lysine-linked MPA (maleimidopropionic acid) DAC
Molecular Weight 3647.28 g/mol
Half-Life Approximately 8 days due to albumin conjugation via the DAC moiety.
Available Sizes 2mg, 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, use within 21 days.

Key Research References

  • Teichman SL, et al. "Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults." J Clin Endocrinol Metab. 2006

Get CJC-1295 DAC from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Hexarelin
Growth
Potent hexapeptide GH secretagogue with additional cardioprotective properties and direct cardiac receptor binding activity.
View Profile → Buy at SP →
ACE-031
Growth
Myostatin pathway decoy receptor researched for increasing lean mass in muscle-wasting conditions.
View Profile → Buy at SP →
PEG-MGF
Growth
Pegylated version of MGF with extended half-life allowing systemic distribution and prolonged satellite cell activation.
View Profile → Buy at SP →